PGLYRP1 and neoplasm: In summary, PDAC cells, particularly CSCs, upregulate PGLYRP1 in response to inflammatory signals, notably TNFα from both tumour and tumour microenvironment (TME) cells (eg, MΦ), as a strategy to mitigate its cytotoxic effects by blocking TNFα/TNFR1 signalling.